免费日韩片_欧美成人精品一区二区男人小说_国产乱码一区二区三区四区_国产精品国产三级国产aⅴ入口_成人看的污污超级黄网站免费_欧美一级在线免费观看_成人午夜免费无码福利片_国产乱人伦偷精品视频色欲_aaa少妇高潮大片免费看_国产精品1234_亚洲精品国产suv一区88_中文字字幕在线中文无码_精品亚洲区_午夜九九九_国产av国片精品jk制服丝袜_色综合亚洲_亚洲成av人片无码bt种子下载_欧美色就色_精品少妇的一区二区三区四区_男人用嘴添女人下身免费视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Latest

Eli Lilly promotes new drug at CIIE

By SHI JING in Shanghai | chinadaily.com.cn | Updated: 2019-11-09 09:43
Share
Share - WeChat

Indianapolis-headquartered pharmaceutical company Eli Lilly and Company attended the second China International Import Expo with its latest medicine Taltz to moderate severe plaque psoriasis.

During the news conference on Thursday, a total of 17 Chinese domestic pharmaceutical companies signed intention agreements with Eli Lilly for the purchase of Taltz. The medicine has been approved by China's National Products Administration in September.

Eli Lilly and Company was not present at last year's CIIE. Julio Gay-Ger, president and general manager of Lilly China, said that they "were positively surprised by the huge success that CIIE had last year".

"So we really want to be part of the CIIE in the second year. We have had in the last 12 months five new molecular entities launched in China. This is very close to our record. More importantly, we have up to 40 new launches in the next seven to 10 years. We are bringing innovations to Chinese patients which will make a huge difference to them," he said.

Gay-Ger said the company has had expectations for Lilly China's sales and business growth.

"China is the second-largest pharmaceutical market in the world today. It is supposed to be the No 1 pharmaceutical market in the future. It is our top priority market and that is why we are investing so heavily and bringing so much innovation here," he said.

Lilly set up its Shanghai office in 1918, which was the first overseas office for the US pharmaceutical company. Lilly China's overall growth rate for the first half of 2019 exceeded 30 percent, reaching a record high throughout the company's 101-year history in China.

Ever since 2013, Lilly has invested about $320 million to build an insulin production facility in Suzhou. The site is set to be an integral part of Lilly's global supply chain, providing insulin products for China, Europe and other markets across the world in 2019.

"In the future, we can have new launches in China simultaneously or almost simultaneously with other markets in the world. That progress is in part because of the great reform that government is taking, which offers great opportunity to have all that happen," he said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE